StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Lesinurad

HCID 53465279
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
1890222-25-9
Standard-SMILES
O=C(O)CSc1nnc(Br)n1-c1ccc(C2CC2)c2ccccc12
InChIKey
FGQFOYHRJSUHMR-UHFFFAOYSA-N
Summenformel
C17H14BrN3O2S
Durchschnittliche Molmasse
404,3 g/mol
Monoisotopische Masse
402,99900979

Überblick

Lesinurad is a member of the class of triazoles that is [(3-bromo-1,2,4-triazol-5-yl)sulfanyl]acetic acid substituted at position 1 of the triazole ring by a 4-cyclopropylnaphthalen-1-yl group. Used for treatment of gout. It has a role as a uricosuric drug. It is a monocarboxylic acid, a member of naphthalenes, an aryl sulfide, a member of triazoles, an organobromine compound and a member of cyclopropanes.

Namen und Bezeichner

Bevorzugter Name
Lesinurad
IUPAC
2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acid
Englischer Name
RDEA 594
Summenformel
C17H14BrN3O2S
Molmasse
404.28

Namen und Synonyme

LESINURAD878672-00-5RDEA594ZurampicRDEA 594RDEA-59409ERP08I3W2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetic acidCHEBI:90929DUZALLO COMPONENT LESINURADDTXSID2010260912-{[5-broMo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
Weitere Namen anzeigen
LesinurdResinadRescindRecinardReginaldResinardLesinurasLesurinad
{[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acidlesinuradum((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)sulfanyl)acetic acid2-((5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl)sulfanyl)acetic acid2-((5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YL)SULFANYL)ACETIC ACIDRefChem:56326M04AB05DTXCID901510348

Datenbank-Bezeichner

CAS
1890222-25-9、1890222-26-0、878672-00-5

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
4,7
Polarare Oberfläche (TPSA)
93,3 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
5
Schwere Atome
24
Formalladung
0
Komplexität
479

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
Human Drugs · 2 Einträge

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physikochemische Eigenschaften

Schmelzpunkt
171 oC · >171oC (dec.)
Siedepunkt
643.7 · 643.7±65.0 °C(Predicted)
Dichte
1.72 · 1.72±0.1 g/cm3(Predicted)
storage temp.
-20 °C · -20°C Freezer, Under inert atmosphere
Löslichkeit
DMSO (Slightly), Methanol (Slightly, Heated)
pka
2.91 · 2.91±0.10(Predicted)
Aggregatzustand
Solid
Farbe
White to Off-White
InChI
InChI=1S/C17H14BrN3O2S/c18-16-19-20-17(24-9-15(22)23)21(16)14-8-7-11(10-5-6-10)12-3-1-2-4-13(12)14/h1-4,7-8,10H,5-6,9H2,(H,22,23)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 5 reports by companies from 2 notifications to the ECHA C&L Inventory.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

In large clinical trials, serum enzyme elevations were rare during lesinurad therapy and no more common than with placebo, and no instances of clinically apparent liver injury attributable to lesinurad were reported. Clinical experience with lesinurad therapy has been limited, but there have yet to be reports of clinically apparent liver injury attributable to its use.

Sicherheitsdaten

wgk
WGK 3
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingLesinurad is extensively bound to proteins in plasma (greater than 98%), mainly to albumin.
PharmacodynamicsDose-dependent reductions in serum uric acid levels and increases in urinary uric acid excretion have been observed following single and multiple oral doses of lesinurad.
Mechanism of Action · 1 Eintrag

Lesinurad inhibits the activity of uric acid transporter 1 (URAT1) and organic anion transporter 4 (OAT4). URAT1 is a major transporter enzyme responsible for reuptake of uric acid from the renal tubules; inhibition of URAT1 function thereby increases excretion of uric acid.

Metabolism/MetabolitesLesinurad undergoes oxidative metabolism mainly via the polymorphic cytochrome P450 CYP2C9 enzyme.
FDA Pharmacological Classification · 6 Einträge

09ERP08I3W

LESINURAD

Established Pharmacologic Class [EPC] - Urate Transporter 1 Inhibitor

Mechanisms of Action [MoA] - Urate Transporter 1 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 3A Inducers

Lesinurad is an Urate Transporter 1 Inhibitor. The mechanism of action of lesinurad is as an Urate Transporter 1 Inhibitor and Cytochrome P450 3A Inducer.

MeSH Pharmacological Classification · 2 Einträge

Agents that increase uric acid excretion by the kidney (URICOSURIC AGENTS), decrease uric acid production (antihyperuricemics), or alleviate the pain and inflammation of acute attacks of gout.

Gout suppressants that act directly on the renal tubule to increase the excretion of uric acid, thus reducing its concentrations in plasma.

Absorption, Distribution and Excretion

Zugehörige Reaktionen

87
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 38744
HRID 38744als Edukt
Reaktionsgleichung von HRID 38745
HRID 38745als Produkt
Reaktionsgleichung von HRID 143474
HRID 143474als Edukt
Reaktionsgleichung von HRID 172212
HRID 172212als Produkt
Reaktionsgleichung von HRID 197994
HRID 197994als Edukt
Reaktionsgleichung von HRID 199579
HRID 199579als Edukt
Reaktionsgleichung von HRID 212933
HRID 212933als Produkt
Reaktionsgleichung von HRID 473266
HRID 473266als Produkt
ZurückSeite 1 von 11

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
PubChem CID
53465279
DTXSID
DTXSID201026091
ChEMBL
CHEMBL2105720
ChEBI
CHEBI:90929
UNII
09ERP08I3W、73WY698HZ7、Q59CAT99RS
EC Number
689-245-8
Nikkaji
J3.671.265A
InChIKey
FGQFOYHRJSUHMR-UHFFFAOYSA-N
SMILES
C(O)(=O)CSC1N(C2=C3C(C=CC=C3)=C(C3CC3)C=C2)C(Br)=NN=1
· 3 Einträge

Oral lesinurad is rapidly absorbed, reaching maximum plasma concentrations (Cmax) within 1–4 h following the administration a single 200 mg dose (in either the fed or fasted state).

Within 7 days following single dosing of radiolabeled lesinurad, 63% of administered radioactive dose was recovered in urine and 32% of administered radioactive dose was recovered in feces. Most of the radioactivity recovered in urine (> 60% of dose) occurred in the first 24 hours. Unchanged lesinurad in urine accounted for approximately 30% of the dose.

The mean steady state volume of distribution of lesinurad was approximately 20 L following intravenous dosing.

Anwendungen · 2 Einträge

BeschreibungApproved by the FDA late in 2015, lesinurad is an urate anion exchange transporter 1 (URAT1) inhibitor for use in the treatment of gout. Ardea Biosciences, which is a subsidiary of AstraZeneca, developed lesinurad to be used in a combination therapy with xanthine oxidase inhibitors for the treatment of hyperuricaemia associated with gout. The approval process is ongoing in several other countries across the globe, with the EMA Committee for Medicinal Products for Human Use giving lesinurad a positive opinion for use as an adjunctive therapy in combination with xanthine oxidase inhibitors to treat hyperuricaemia.

VerwendenLesinurad is used to synthesize febuxostat which is a non-purine analog inhibitor of xanthine oxidase. Febuxostat is approved by the European Medicines Agency and the US Food and Drug Administration for treating gout.

Ergänzende Hinweise

DefinitionChEBI: A member of the class of triazoles that is [(3-bromo-1,2,4-triazol-5-yl)sulfanyl]acetic acid substituted at position 1 of the triazole ring by a 4-cyclopropylnaphthalen-1-yl group. Used for treatment of gout.